Heinz Ludwig1, Carsten Bokemeyer2, Matti Aapro3, Mario Boccadoro4, Pere Gascón5, Kris Denhaerynck6,7, Andriy Krendyukov8, Ivo Abraham6,9,10,11, Karen MacDonald6. 1. Medizinische Abteilung I - Onkologie und Haematologie, Wilhelminenspital, Wienpäoh, Montleartstraße 37, 1160 Vienna, Austria. 2. Department of Oncology, Hematology & BMT with Section of Pneumology Universitaetsklinikum Hamburg Eppendorf, Martinistraße 52, 20246 Hamburg, Germany. 3. Cancer Center, Clinique de Genolier, Route du Muids 3, 1272 Genolier, Switzerland. 4. Dipartimento di Oncologia e Ematologia, Azienda Ospedaliero Universitaria S Giovanni Battista di Torino, Via Cherasco 15, 10126 Torino, Italy. 5. Department of Hematology-Oncology, Division of Medical Oncology, Hospital Clínic de Barcelona, University of Barcelona, Carrer de Villarroel 170, 08036 Barcelona, Spain. 6. Matrix45, Tucson, 6159 West Sunset Road, Tucson, AZ 85743, USA. 7. Department of Public Health, University of Basel, Bernoullistrasse 28, 4056 Basel, Switzerland. 8. Hematology and Oncology, Hexal AG, Industriestraße 25, 83607 Holzkirchen, Germany (formerly). 9. Department of Pharmacy Practice & Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA. 10. Center for Health Outcomes & PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA. 11. Department of Family & Community Medicine, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.
Abstract
AIM: This study aimed to report patterns of biosimilar filgrastim prophylaxis and outcomes of chemotherapy-induced neutropenia (CIN)/febrile neutropenia (FN) in patients with hematological malignancies or solid tumors. PATIENTS & METHODS: MONITOR-GCSF is a real-world study of 1447 cancer patients receiving CIN/FN prophylaxis with biosimilar filgrastim (solid tumors: 77.2%; hematological malignancies: 22.8%). RESULTS: Differences in prophylaxis intensity and day of initiation relative to guideline recommendations were observed. In hematology patients, higher rates of CIN and FN occurred at cycle level, and rate of FN was higher at patient level (9.1 vs 5.0% in solid tumor patients). CONCLUSION: Adequate GCSF support in hematology and solid tumor patients is important to prevent CIN/FN and related hospitalizations and chemotherapy disturbances.
AIM: This study aimed to report patterns of biosimilar filgrastim prophylaxis and outcomes of chemotherapy-induced neutropenia (CIN)/febrile neutropenia (FN) in patients with hematological malignancies or solid tumors. PATIENTS & METHODS: MONITOR-GCSF is a real-world study of 1447 cancerpatients receiving CIN/FN prophylaxis with biosimilar filgrastim (solid tumors: 77.2%; hematological malignancies: 22.8%). RESULTS: Differences in prophylaxis intensity and day of initiation relative to guideline recommendations were observed. In hematology patients, higher rates of CIN and FN occurred at cycle level, and rate of FN was higher at patient level (9.1 vs 5.0% in solid tumorpatients). CONCLUSION: Adequate GCSF support in hematology and solid tumorpatients is important to prevent CIN/FN and related hospitalizations and chemotherapy disturbances.
Authors: Matias F Martinez; Enzo Alveal; Tomas G Soto; Eva I Bustamante; Fernanda Ávila; Shrikant I Bangdiwala; Ivonne Flores; Claudia Benavides; Ricardo Morales; Nelson M Varela; Luis A Quiñones Journal: Pharmgenomics Pers Med Date: 2020-08-19